Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age

Seqirus

Status and phase: Completed; Phase 2

Conditions: Influenza, Human

Treatments: Biological: Experimental: aIIV-C Investigational aIIV-C will be administered as a single dose intramuscularly on Day 1; Biological: Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1; Biological: Experimental: IIV-A Investigational IIV-A will be administered as a single dose intramuscularly on Day 1; Biological: Active Comparator: Licensed IIV IIV will be administered as a single dose intramuscularly on Day 1

Study type: Interventional

Funder types: Industry

Identifiers

NCT05501561

V201_07

Details and patient eligibility

About

This Phase 2, randomized, observer-blind, dose-confirmation Clinical study is evaluating different formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine. Approximately 1000 subjects are to be randomized into 1 of 4 possible treatment groups with 250 participants per group. Every participant will receive an influenza vaccine injection on Day 1 and will be followed up for approximately 6 months following injection. The primary immunogenicity analysis is based on Day 29 serology data.

Enrollment: 1,056 patients

Sex: All

Ages: 50+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

In order to participate in this study, all subjects must meet ALL of the inclusion criteria described.

1. Individuals ≥50 years of age on the day of informed consent.

2. Individuals who have voluntarily given written consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry.

3. Individuals who can comply with study procedures including follow-up .

4. Males, females of non-childbearing potential or females of childbearing potential who are using an effective birth control method, at least 30 days prior to informed consent, which they intend to use for at least 2 months after the study vaccination.

Exclusion criteria

In order to participate in this study, all subjects must not meet ANY of the exclusion criteria described below:

1. Females of childbearing potential who are pregnant, lactating, or who have not adhered to a specified set of contraceptive methods from at least 30 days prior to informed consent and who do not plan to do so for at least 2 months after the study vaccination.

2. Progressive, unstable or uncontrolled clinical conditions.

3. Hypersensitivity, including allergy, to any component of vaccines whose use is foreseen in this study.

4. History of any medical condition considered an adverse event of special interest (AESI).

5. Known history of Guillain-Barré syndrome or another demyelinating disease such as encephalomyelitis and transverse myelitis.

6. Clinical conditions representing a contraindication to intramuscular administration of vaccines or blood draw.

7. Abnormal function of the immune system resulting from:

   1. Clinical conditions.
   2. Systemic administration of corticosteroids (PO/IV/IM) at a dose of ≥20 mg/day of prednisone or equivalent for more than 14 consecutive days within 90 days prior to informed consent5.
   3. Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent.

8. Receipt of immunoglobulins or any blood products within 180 days prior to informed consent.

9. Receipt of an investigational or non-registered medicinal product within 30 days prior to informed consent.

10. Receipt of any COVID-19 vaccine within 14 days (non-replicating vaccines) or 28 days (replicating vaccines) prior to informed consent or plan to receive any COVID-19 vaccine within 7 days from study vaccination

11. Individuals who received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to informed consent or who are planning to receive any vaccine within 28 days from the study vaccines.

12. Study personnel or immediate family or household member of study personnel.

13. Receipt of any influenza vaccine within 6 months prior to informed consent, or plan to receive an influenza vaccine during the study period.

14. Acute (severe) febrile illness,

15. Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study.

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

1,056 participants in 4 patient groups

IIV-A Investigational

Experimental group

Treatment:

Biological: Experimental: IIV-A Investigational IIV-A will be administered as a single dose intramuscularly on Day 1

aIIV-B Investigational

Experimental group

Treatment:

Biological: Experimental: aIIV-B Investigational aIIV-B will be administered as a single dose intramuscularly on Day 1

aIIV-C Investigational

Experimental group

Treatment:

Biological: Experimental: aIIV-C Investigational aIIV-C will be administered as a single dose intramuscularly on Day 1

Licensed IIV

Active Comparator group

Treatment:

Biological: Active Comparator: Licensed IIV IIV will be administered as a single dose intramuscularly on Day 1